NCT01155778View on ClinicalTrials.gov

Safety, Tolerability, Ascending Dose and Dose Frequency Study of rhHNS Via an IDDD in MPS IIIA Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 1, 2010

Primary Completion Date

September 1, 2012

Study Completion Date

September 1, 2012

Conditions
Mucopolysaccharidosis (MPS)
Interventions
BIOLOGICAL

Recombinant human heparan N-sulfatase (rhHNS)

Trial Locations (2)

1105 AZ

Emma Children's Hospital, Academic Medical Center, Amsterdam

M13 9WL

St. Mary's Hospital, Manchester

Sponsors

Lead Sponsor

Shire
All Listed Sponsors
lead

Shire

INDUSTRY